Tilray Brands, Inc. (TLRY) Strengthens U.S. Footprint With Long-Term Carlsberg Partnership

Tilray Brands, Inc. (NASDAQ:TLRY) is among the 11 Best Pot Stocks to Buy According to Hedge Funds.

On February 18, Tilray Brands, Inc. (NASDAQ:TLRY) announced that it has entered into an exclusive licensing agreement, effective January 1, 2027, with Carlsberg Group, one of the world’s premier brewing organizations and among the largest globally by revenue. Under the agreement, Tilray has been granted a multi-year license to produce, market, sell, and distribute Carlsberg, Carlsberg Elephant, 1664, and Kronenbourg 1664 Blanc branded beers across all channels in the United States beginning January 1, 2027. The agreement carries an initial five-year term with an automatic five-year renewal contingent on performance criteria. For potential investors, this represents a meaningful strategic expansion of Tilray’s beverage alcohol portfolio, providing access to globally recognized premium brands with established consumer demand. The partnership enhances Tilray’s scale within the U.S. beer market, diversifies revenue streams beyond cannabis, and strengthens long-term visibility through a contractual multi-year framework tied to performance benchmarks.

On February 12, Tilray Pharma, the pharmaceutical division of Tilray Brands, Inc. (NASDAQ:TLRY), announced that its European pharmaceutical distribution arm, CC Pharma, entered into a strategic agreement with Smartway Pharmaceuticals to expand the availability of pharmaceutical products across the United Kingdom. Smartway’s leadership emphasized the agreement’s focus on continuity of supply and improved access to regulated medicines throughout UK healthcare channels. For potential investors, this development signals further geographic and operational expansion within Tilray’s distribution segment, reinforcing the company’s positioning as a diversified consumer packaged goods and pharmaceutical platform. The agreement broadens Tilray’s footprint in the European pharmaceutical supply chain, supports incremental revenue opportunities in regulated markets, and strengthens recurring distribution-based revenue streams.

Tilray Brands, Inc. (NASDAQ:TLRY) operates as a global consumer packaged goods company focused on medical cannabis research, cultivation, processing, distribution, and beverage alcohol operations, with segments spanning Cannabis, Distribution, and Beverage. With 12 hedge funds having stakes in the company as of Q3 2025, as recorded by Insider Monkey, Tilray Brands is among the best pot stocks to buy according to hedge funds.

While we acknowledge the potential of TLRY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Retail Stocks to Buy According to Analysts and 13 Best Internet of Things (IoT) Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.